ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CNTA Centessa Pharmaceuticals PLC

11.04
-0.36 (-3.16%)
10 Aug 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Centessa Pharmaceuticals PLC NASDAQ:CNTA NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.36 -3.16% 11.04 11.08 11.67 11.61 10.95 11.42 332,516 01:00:00

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

27/03/2023 1:00pm

GlobeNewswire Inc.


Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart


From Aug 2022 to Aug 2024

Click Here for more Centessa Pharmaceuticals Charts.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the following investor conferences:

Event: Guggenheim Genomic Medicines and Rare Disease DaysDate: Monday, April 3, 2023Location: New York, NYFireside Chat: 9:35 AM ET

Event: Jefferies & Venrock Boston Biotech SummitDate: Wednesday, April 12, 2023

Where applicable, the presentation slides and/or a link to the live webcast of the event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations.

About Centessa PharmaceuticalsCentessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit http://www.centessa.com/, which does not form part of this release.

Contact:Kristen K. Sheppard, Esq.SVP of Investor Relationsinvestors@centessa.com

1 Year Centessa Pharmaceuticals Chart

1 Year Centessa Pharmaceuticals Chart

1 Month Centessa Pharmaceuticals Chart

1 Month Centessa Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock